Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy

HIV Medicine

Volumn 7, Issue 3, 2006, Pages 181-185

  Moyle, Graeme J ^a   Brown, S ^a   Lysakova, L ^b   Barton, S E ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

Lipoatrophy; PLLA; Poly L lactic acid; Sculptra New Fill

Indexed keywords

POLYLACTIC ACID;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FACE MUSCLE; FACIES; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFECTION; INJECTION SITE BLEEDING; INJECTION SITE CONTUSION; INJECTION SITE DISCOMFORT; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE INFLAMMATION; INJECTION SITE NODULE; INJECTION SITE PAIN; LIPOATROPHY; LONG TERM CARE; OPEN STUDY; PATIENT SATISFACTION; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; SKIN DEFECT; VISUAL ANALOG SCALE;

ADULT; BIOCOMPATIBLE MATERIALS; COSMETIC TECHNIQUES; DRUG IMPLANTS; FACE; FEMALE; FOLLOW-UP STUDIES; HIV-1; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INJECTIONS; LACTIC ACID; MALE; PILOT PROJECTS; POLYMERS; SAFETY; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 33644764029     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2006.00342.x     Document Type: Article

References (16)

1. Collins E, Wagner C, Walmsley S. Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Read 2000; 10: 546-550.
2. Power R, Tate HL, McGill SM, Taylor C. A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individuals. Sex Transm Infect 2003; 79: 137-141.
3. Martinez E, Garcia-Viejo MA, Blanch L. Lipodystrophy syndrome in patients with HIV infection: Quality of life issues. Drug Saf 2001; 24: 157-166.
4. John M, McKinnon EJ, James IR et al. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/ abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir Immune Defic Syndr 2003; 33: 29-33.
5. Moyle GJ, Baldwin C, Langroudi B, Mandalia S, Gazzard BG. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr 2003; 33: 22-28.
6. Martin A, Smith DE, Carr A et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: The MITOX Extension Study. AIDS 2004; 18: 1029-1036.
7. Valantin MA, Aubron-Olivier C, Ghosn J et al. Polylactic acid implants (New-Fill®) to correct facial lipoatrophy in HIV-infected patients: Results of the open-label study VEGA. AIDS 2003; 17: 2471-2477.
8. Moyle GJ, Lysakova L, Brown S et al. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med 2004; 5: 82-87.
9. Zigmond AS, Snalth RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-370.
10. Vleggaar D, Bauer U. Facial enhancement and the European experience with poly-L-lactic acid. J Drugs Dermatol 2004; 3: 542-547.
11. Woerle B, Hanke CW, Sattler G. Poly-L-lactic acid: A temporary filler for soft tissue augmentation. J Drugs Dermatol 2004; 3: 385-389.
12. Douglas RS. Lumps and bumps: Late postsurgical inflammatory and infectious lesions. Plastic Reconstruct Surg 2003; 112: 1923-1928.
13. Friedman PM, Mafong EA, Kauvar AN, Geronemus RG. Safety data of injectable nonanimal stabilized hyaluronic acid gel for soft tissue augmentation. Dermatol Surg 2002; 28: 491-494.
14. Bergeret-Galley C. Comparison of resorbable soft tissue fillers. Aesthetic Surg J 2004; 24: 33-46.
15. Dermik Laboratories. Sculptra™ Product Information. http://www.sculptra.com/US/resources/SculptraPI.pdf 2005.
16. Bauer U. Correction of facial deformities with poly-L-lactic acid: 40-month follow-up. J Eur Acad Dermatol Venereol 2004; 18: 193-557.